(Q44763941)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

title

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

Sean Emery

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

8

Matthew Law

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

author name string

Andrew Carr

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

Cassy Workman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

Dianne Carey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

Allison Martin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

David Baker

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

Handan Wand

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

Katherine Samaras

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

David A Cooper

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

Rosey investigators

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

language of work or name

English

0 references

publication date

1 February 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

volume

363

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

issue

9407

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

page(s)

429-438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

Toxicity of antiretroviral therapy and implications for drug development

23 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Combination antiretroviral therapy and the risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Indinavir inhibits sterol-regulatory element-binding protein-1c-dependent lipoprotein lipase and fatty acid synthase gene activations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

A futile metabolic cycle activated in adipocytes by antidiabetic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Reduced IRS-2 and GLUT4 expression in PPARgamma2-induced adipocytes derived from C/EBPbeta and C/EBPdelta-deficient mouse embryonic fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2915489-5

7 January 2021

10.1016/S0140-6736(04)15489-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14962523%20AND%20SRC:MED&resulttype=core&format=json

23 November 2019

1 reference